Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials

Published:2021-11-15 Issue:6 Volume:15 Page:895-903
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Heo Jeong¹^ORCID,Kim Yoon Jun²^ORCID,Lee Jin-Woo³^ORCID,Kim Ji Hoon⁴^ORCID,Lim Young-Suk⁵^ORCID,Han Kwang-Hyub⁶^ORCID,Jeong Sook-Hyang⁷^ORCID,Cho Mong⁸^ORCID,Yoon Ki Tae⁸^ORCID,Bae Si Hyun⁹^ORCID,Crown Eric D.¹⁰^ORCID,Fredrick Linda M.¹⁰^ORCID,Alami Negar Niki¹⁰^ORCID,Asatryan Armen¹⁰^ORCID,Kim Do Hyun¹¹^ORCID,Paik Seung Woon¹²^ORCID,Lee Youn-Jae¹³^ORCID

Affiliation:

1. Department of Internal Medicine, Pusan National University College of Medicine and Medical Research Institute, Pusan National University Hospital, Busan, Korea

2. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

3. Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea

4. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

5. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

6. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

7. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

8. Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea

9. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

10. Abbvie Inc., North Chicago, IL, USA

11. AbbVie Korea, Ltd., Korea

12. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

13. Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2021/015/GNL015-06-895.pdf

Reference29 articles.

1. World Health Organization (WHO). Global hepatitis report, 2017 [Internet]. Geneva: WHO; c2017 [cited 2020 Oct 28]. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.

2. European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;69:461-511.

3. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

4. Global distribution and prevalence of hepatitis C virus genotypes

5. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-08-14

2. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea;The Korean Journal of Gastroenterology;2024-03-25

3. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals;Gut and Liver;2023-04-20

4. Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid;Viruses;2023-02-09

5. Current Landscape of HCV Therapeutics;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01